{"certainAgreement":{"piSponsorEmployee":true,"restrictiveAgreement":false},"limitationsAndCaveats":{"description":"An interim analysis found the intervention to be futile. Therefore, the VIVA trial was ended effective July 31st, 2022, for the University of Washington clinic, and December 31st, 2022, for the University of Alabama Birmingham clinic. Participants were offered the choice of continuing any outstanding visits until the end of the study at the respective sites."},"pointOfContact":{"email":"mmadelei@fredhutch.org","organization":"Fred Hutchinson Cancer Center","phone":"206-667-4630","title":"Margaret M. Madeleine, PhD"}}